MedPath

Quality of life of patients with actinic keratoses and/or a superficial basal cell carcinoma treated with 5% Imiquimod cream.

Recruiting
Conditions
10040900
actinic keratoses/solar keratoses and superficial basal cell carcinoma/basal cell cancer
Registration Number
NL-OMON33695
Lead Sponsor
Erasmus MC, Universitair Medisch Centrum Rotterdam
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
500
Inclusion Criteria

Patients with actinic keratoses and/or a superficial basalcellcarcinoma, PA not neseccary
Patients are capable of treating themselve or know a person who can assist them
Patients older than 18 years
Signed informed consent

Exclusion Criteria

patients mentally or physically not capable of filling out the questionnaires/diary
Patienst who are not able to understand Dutch in a way they need to to fill out the questionnaires/diary

Study & Design

Study Type
Observational non invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>The proportion of patients of which HRQOL (quality of life) increases after<br /><br>treatment, the proportion of patients satisfied with the treatment and the<br /><br>proportion of patients with therapy adherence >=80% will be described. HRQOL<br /><br>scores before and after treatment will be compared by the Mann-Whitney test.<br /><br><br /><br>Regressioncoefficients (confidence incidence)will describe which demografic and<br /><br>diseasecharacteristics are related to a change in HRQOL. With multivariable<br /><br>logistic regression we will analyze what variables are markers for (good)<br /><br>therapy adherence and treatment satisfaction ( Adjusted odds ratios and<br /><br>confidence interval).</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>not applicable</p><br>
© Copyright 2025. All Rights Reserved by MedPath